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ABSTRACT
Objectives: To assess the significance of pathologic ultrastaging (PU) of sentinel (SLN) and non-sentinel (nSLN) lymph 
nodes (LNs) and the influence on cancer staging in patients with International Federation of Gynecology and Obstetrics 
(FIGO) stage IA2-IB1 cervical cancer.
Material and methods: A retrospective study was conducted with 54 patients divided into two equal-sized groups. In test 
group (n1), at least one SLN/patient was detected with blue dye. All excised LNs in this group were subjected to PU (4 µm 
slices/150 µm intervals) with hematoxylin-eosin staining and immunohistochemistry (AE1-AE3 antibodies). In none of the 
control group (n2) was PU performed, but in 2 patients SLN concept was performed. Patients in both groups underwent 
radical hysterectomy and lymphadenectomy. The effect of PU was expressed in puTNM and compared with both standard 
pTNM and FIGO systems. The influence of PU on patients’ disease-free survival (DFS) and overall survival (OS) was assessed 
using Kaplan-Meier curves.
Results: In total, 516 LNs were extracted (66 SLNs, 36% bilaterally). Micrometastases (MIC) or isolated tumor cells (ITC) were 
detected in 34 of the 482 LNs (7.1%), including 16 MICs and 9 ITC in non-SLNs. False negative rates were: 3.7%/side-specific, 
and 7.4%/both sides. The use of PU resulted in stage change in 2 cases (N and M status change), FIGO stage did not changed. 
No PU impact on DFS or OS was observed.
Conclusions: The risk of TNM stage migration in early cervical cancer is low, is more likely in inattentively evaluated patients, 
and has indeterminate prognostic and predictive value. Selection of cases with cT ≤ 2 cm and cN0 is sufficient to avoid 
the risk of improper staging.
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INTRODUCTION
Sentinel lymph node detection (SLND) is a strategy 
involving closer inspection of the lymph nodes (LNs) 
which are most likely to be the first draining nodes of 
the tumor and to harbor malignancy [1]. The clinical use 
of sentinel lymph node (SLN) biopsy was a significant 
milestone in surgical oncology [2]. In gynecologic oncol-
ogy, SLN biopsy has found its place in the surgical treat-
ment of patients with vulvar cancer [3]. In cervical cancer 
(CC) and endometrial cancer, the role of SLN staining 
and detection is still being intensely investigated [4–7]. 
Cervical cancer spreads primarily locally and through 
the lymphatic system. LN status is one of the most im-
portant predictive and prognostic factors in early stage 
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CC detection, where other metastases usually occur at 
more advanced stages. An increase in early CC diagno-
ses allows for adjusting the extent of uterine resection 
to the stage of the disease. The same is valid for the 
scope of lymphadenectomy (LND). When LN metastases 
is considered essential, SLND seems to be an alternative 
to complete pelvic LND for some patients. However, the 
benefits of SLND may be observed in all stages [8–11]. The 
method primarily allows, among others, the detection of 
micrometastases (MICs) that have been proven to have 
the same significance for the patient’s prognosis as the 
detection of macrometastases (MAC) [6]. 
The US National Comprehensive Cancer Network 
(NCCN) strongly recommends the application of SLN con-
cept in early-stage CC (as a part of LND - Recommendation 
2A) [12], and the same is stated in the European Society 
of Gynecology and Obstetrics (ESGO) Guidelines [13]. 
Early-stage CC includes stage IIA1 according to the Inter-
national Federation of Gynecology and Obstetrics (FIGO) 
staging system [14] or is defined by sizes up to 2–4 cm 
[11, 13, 15]. 
The lymph node sparing approach induces some 
uncertainties. It is possible that small metastases (MICs) 
may stay occult unless a non-SLNs (nSLNs) assessment 
is performed. Recently, FIGO finally added LNs status to 
their staging system, because the N feature is the most 
important prognostic factor in many cancers [14]. Unfor-
tunately, imaging methods for smaller metastases (up to 
5 mm) still have their limitations [16, 17]. 
Objectives
The aim of this study was to assess the risk of 
non-sentinel low volume LN disease (LVLND) coverage 
of MIC and/or isolated tumor cells (ITC) in cases of both 
positive and negative SLN, when all LNs are examined 
by pathological ultrastaging (PU) in early-stage CC. 
Therefore, it was expected that the histopathological 
evaluation of all LNs (nSLNs) by PU should validate SLND 
as a method. 
Meanwhile, PU, a non-routine method used for evalu-
ation of LNs, may potentially allow the post-operative 
detection of stage migration. Clarifying the extent and 
role of such migration is important in the context of 
the adequacy of surgical recovery and adjuvant therapy 
planning. 
Comparing the FIGO and TNM staging systems, as 
well as TNM including PU, together with understanding 
the significance and possible threats of cancer stag-
ing changes are important for enabling us to balance 
therapy between the desire to minimize unfavorable 
sequelae of surgery and maximize the oncological out-
comes.
MATERIAL AND METHODS
Between the 1st of January 2010 and the 30th of April 
2014, 122 patients undergoing surgery for CC FIGO stage 
IA to IIA2, were entered into the study database, 54 of 
them were FIGO IA2-IB1. This group of 54 patients was 
divided into two equal groups: n1 (PU performed) and 
n2 (control, no PU performed). Group n1 included 1 case 
of SLND alone, 26 cases of SLND within LND, and the 
re-evaluation of all extracted LNs. Group n2 included 
25 cases of LND without SLN concept, and 2 cases of 
unsuccessful SLND. All patients underwent surgery suit-
able to their FIGO stage according to the current NCCN 
guidelines. The patients either received cisplatin-based 
chemoradiation, or only underwent surgery where adju-
vant treatment was not advisable.  
Technique
Before surgery, 1 mL (10 mg) of methylene blue (Ster-
op Pharmacobel, Belgium) was injected in each of four 
punctures of the vaginal portion of the cervix (22 G) in 
the 3, 6, 9 and 12 o’clock locations, approximately 0.5 cm 
from the tumor border, and perpendicular to the cervix 
surface. This was administered 10–15 minutes prior to sur-
gical skin incision and 20–25 minutes prior to opening of 
the retroperitoneal space. Then the radical hysterectomy 
was performed (Piver class III in most cases) [18]. The LNs 
were considered as “sentinel” by their blue staining as 
specified by the surgeon intraoperatively or by the pa-
thologist postoperatively (in cases where the staining was 
invisible macroscopically). Lymph nodes were removed 
by separating the labeled (SLNs) from the non-labeled 
nodes (nSLNs). If there was no labeling on a side, all LNs 
on that side were regarded as nSLN. 
Staging procedure 
Lymph node samples were embedded in paraffin 
blocks and subjected to standard histopathological analy-
sis. After the final diagnosis was provided, the LNs were 
subjected to multiple sectioning every 150 µm and evalu-
ated by PU. In brief, the method is based on layered cut-
ting of the paraffin-embedded tissues in 4 µm micro cuts 
at even distances apart (150 µm). The slices were placed 
on silanized glass slides, two samples from each level, 
the first stained with hematoxylin and eosin (HE), and the 
second subjected to immunohistochemistry (IHC) with 
cytokeratin (CK) monoclonal antibodies AE1/AE3 (Dako, 
Denmark). LNs were simultaneously examined by two 
researchers (MS and SW) under an optic microscope and 
measured manually (the maximal diameter of each lesion 
was noted). The schematic representation of a LN with 
MAC, MIC and ITC is shown in Figure 1. The occurrence 
of MAC or MIC, and of ITC, in each LN that had been 
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removed was determined separately. The results have 
been included in their entirety in the classification of 
pathological (p) TNM as “puN1”, “puN1mi” and “puN0i (+)”. 
In the latter two cases, if the LNs contained only MIC(s) 
and/or only ITC, the number of LNs involved are given in 
brackets, for example: “puN1mi,I (+) (3LN, 1LN)”. If the LNs 
contained MAC or MIC/ITC, this information is given at 
the end of Figure 1 in parentheses. With respect to SLNs, 
it was assumed that in cases of the successful staining of 
one or both sides of the pelvis the additional information 
on the ratio of positive LNs to the number of SLNs should 
be given in parentheses. 
Statistical analysis
The study involved the independence chi-square test 
to analyze the relationship between dichotomous vari-
ables. In cases of quantitative predictors, a normality as-
sumption was evaluated using Kolmogorov’s test with the 
Lilliefors correction. Then the t-Student’s test was used 
to examine the relationship between normally distrib-
uted predictors and dichotomous dependent variables, 
whereas the nonparametric Mann-Whitney U test was 
used for non-normally distributed predictors. Receiver 
Operating Characteristic (ROC) curves were determined 
and the AUC (area under ROC) was calculated to obtain 
the power of the discriminant variables. The criterion for 
selection of the optimal cut-off point was the maximiza-
tion of the Youden index. In all the tests, the significance 
level was p = 0.05, and analysis was performed using 
Statistica 10 (StatSoft Inc., Poland). 
RESULTS
The general characteristics of the patients are sum-
marized in Table 1. LSVI was the only statistically sig-
nificant difference between groups n1 and n2. Detailed 
information on cancer staging of the n1 group is given 
in Table 2. In the n1 group, the bilateral detection of SLN 
was found in 11 of 27 patients (36%), which was a total 
of 38 hemi-pelvises out of 54 (70%). A total of 516 LNs 
(5599 slides) were removed from the whole study group 
(mean 19.4 per patient), and this included 66 SLNs (12.8%, 
mean 2.5 per patient). Lesions in LNs were found in 11 out 
of 27 patients, all at stage FIGO IB1 (2009-2017). In total, 
56 LNs (10.9%) contained lesions, and the most prevalent 
lesions were MAC (22 times), MIC (22 times), and ITC 
(12 times). Micrometastases were found in 6 (9.1%) of the 
SLNs and in 16 (3.6%) of the 450 nSLNs. Macrometastases 
were found in 7 SLNs and ITC in 3 SLNs; whereas 15 nSLNs 
contained MAC and 9 nSLNs contained ITC. 
Retrospectively, our intention of using SLN concept and 
PU allowed the detection of a larger number of LNs com-
pared with a routine approach with surgery and examina-
tion (resulting in an average increase of 4 LNs extracted, 
p = 0.046). On average, patients with unilateral staining were 
about 9.5 years older than those identified with bilateral 
SLND (p=0.0326). In 10 cases, MIC was found in both exami-
nations (HE and IHC), and in 1 case by IHC only. In 3 patients, 
metastasis or ITC in LNs were found in the SLN(s) only, in 
3 cases exclusively in nSLN(s), and in 5 patients, changes 
occurred in both SLN(s) and nSLN(s) (Tab. 3). A relationship 
was found between the occurrence of MAC in SLN and MIC 
in nSLN (p = 0.0072). The tumor metastases data on LN status 
(SLN and nSLN), including the number of cases and corre-
sponding ITC in LNs, are presented in Table 4. Quantitative 
and topographic division are shown in Figure 2.
Prognostic factors and nSLN status
In 24 cases of n1 (88.8%) the SLN status predicted the 
status of nSLN. In the n1 group the sensitivity and specificity 
of SLN detection per site was 60% and 89.3%, respectively. 
Lesions in nSLN were significantly more frequent if the pri-
mary lesion was > 2 cm than for those of ≤ 2 cm (73% vs 
27%, respectively, p = 0.01068); and in the cases of a positive 
LVSI the significance was p = 0.04285. The histological type 
of tumor, grade and depth of infiltration did not show any 
statistically significant relationship with MAC, MIC and ITC 
detected in all LNs and in the subgroup of nSLNs as well. 
In patients with MACs in SLNs, the MACs and MICs in the 
nSLNs were detected significantly more frequently, without 
affecting the incidence of ITC (p = 0.0142). The cutoff value 
of invasion depth for the risk of events in LNs was ≥ 8 mm 
as measured by Youden’s index (Fig. 3).
False negatives cases
Results considered as false negative cases, were 
found in three patients of n1. The actual false negative 
Figure 1. Schematic representation of the definitions of macro-, 
micrometastases and isolated tumor cells
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rate was 2/27 (7.4%) per patient and the side-specific 
false negative rate was 1/38 (2.6%). This is due to the 
fact that ITC are not metastases; and in the case of the 
side-specific false negative, the coloration was present 
on the opposite hemi-pelvis to the false negative result 
(Tab. 5). 
Stage migration
Extending the histopathological examination of all 
LNs allowed the identification of additional metastases 
in 34 of 482 LNs (7.1%) — LVLND; comprised of 22 MIC 
and 12 ITC. After PU was performed, the N feature was 
adjusted to the actual stage from pN0 to p(u)N1 in 1 case 
(patient PM, detection of MIC in pelvic nSLNs, 3.7%). 
In one other case, the M feature was changed from cMx 
to p(u)M1 (patient MW, PALN nSLN, 3.7%), as shown 
in Tables 2 and 6. A detailed summary of changes to both 
the TNM and FIGO classifications after PU was performed 
is presented in Table 6. These changes and the differences 
between the groups in the classifications prior to, and 
after PU did not reach statistical significance, and did not 
influence the results.
Survival analysis
During the observation period, with a median of 
4.2 years, comparing the two groups (n1 – PU and n2 – no PU), 
and also comparing between the PU group of pa-
tients and those without LN-positivity (including ITC), 
against the control group, there was no statistically sig-
nificant difference observed in either the overall survival 
(OS) rate or the disease-free survival (DFS) rate of the 
patients (Fig. 4).
Table1. Patients and tumor characteristics in study (n1) and control (n2) groups
Group n1 = 27 (%) n2 = 27 (%) p-value
Age (median age 54, range 23–65)
20–39
40–59
≥ 60
8 (30)
12 (44)
7 (26)
2 (7.5)
18 (66.5)
7 (26)
P = 0.354
BMI* (median, range) 25 (19–37) 23 (17.5–39) P = 0.608
Stage according to FIGO (2009–2017)
IA2
IB1
1 (96)
26 (4)
2 (7.5)
25 (92.5)
P = 0.55245
Type of surgery
PRS II (pLND)
PRS III (pLND)
PRS III (p+paLND)
PRS III (pLND)
PRS III (SLND)*
PRS III (pLND)
1 (4)
19 (70)
3 (11)
2 (7)
1 (4)
1 (4)
2 (7.5)
18 (66.5)
5 (18.5)
0
2 (7.5)
0
p^ = 0.7613
Histopathological tumor size in cm (median, range) 2.5; 0.6–5.5 2.5; 0.45–6.0 P = 0.567
Histology
Squamous cell carcinoma
Adenocarcinoma
Adenosquamous carcinoma
24 (89)
1 (7)
2 (4)
25 (92.5)
2 (7.5)
0
P = 0.308
Number of resected and examined lymph nodes 516 382
Number of patients with positive lymph nodes (MAC+/MIC+) 7 (26) 5 (18.5) p* = 0.5076
Number of patients with events in lymph nodes (MAC+/-MIC+/-ITC) 11 (41) 5 (18.5) p* = 0.0706
LVSI 15 (56) 7 (26) p^ = 0.037
Grade
G1
G2
G3
2 (7)
15 (56)
10 (37)
4 (15)
20 (74)
3 (11)
P = 0.07615
Depth of invasion
≤ 10 mm
10.1–19.9 mm
≥ 20 mm
16 (59)
10 (37)
1 (4)
13 (48)
13 (48)
1 (4)
P = 0.555
BS — bilateral salpingectomy; BSO — bilateral salpingo-oophorectomy; BMI — body mass index (calculated by Web application at https://www.nhlbi.nih.
gov/health/educational/lose_wt/BMI/bmicalc.htm; CON — cone biopsy; FIGO – International Federation of Gynecology and Obstetrics; G — grade; pLND — pelvic 
lymphadenectomy; paLND — paraaortic lymphadenectomy; PRS — hysterectomy according to Piver classification; SLND — sentinel lymph nodes dissection; p 
— probability of U-Mann-Whitney test (corrected for continuity); p^ — probability of the Chi-square test of independence; p* — two-tailed test for two structure 
indicators
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DISCUSSION
The purpose of our study was to evaluate the reliability 
of the determination of metastases in nSLNs by examining 
the presence of any type of tumor deposits (MAC, MIC, ITC) 
in early-stage CC and by comparing the outcomes with 
a group of patients without sentinel concept. Using one 
labeling method (36% with double-sided staining), the 
false positive rate was 3.7% for hemipelvis, and 7.4% in 
total. In this study, a change of N stage (from pN0 to 
puN1) took place in one case. In one out of four cases of 
para-aortic lymph nodes (PALNs) removal, an unstained 
LN with MIC (distant metastasis) was confirmed, result-
ing in the change of that patient’s cancer stage (puM1). 
The metastatic lesion size was 2 mm, which was initially 
invisible in routine processing. There were no differences 
in survival between groups, but the groups differed in 
their LVSIs and the number of LNs removed. The first issue 
of differing LVSIs can be explained only by contingency, 
and the latter of the number of LNs removed, by improved 
“navigation” in the pelvis using SLND. Besides these facts, 
the ultrastaging patients’ material was collected after that 
of the non-ultrastaging ones. There was no influence of 
PU on the prognoses, which may be an effect of the small 
size of our study group (n = 27) which would impact the 
statistically defined differences, and in such a case, even 
a 15–20% difference in hazard ratio will be insignificant.
In this study only one marking method was utilized 
– blue dye. In our previous study, the bilateral detection 
Table 2. Detailed presentation of data on the staging of each patient in the test group (n1 = 27)
No. Initials
FIGO 
staging 
(2009–
2017)
Primary pTNM 
after surgery¶  Restaging after ultrastaging (puTNM)
Depth of 
invasion 
(mm)
LVSI Type of surgery
Lymph 
nodes
1. JB IB1 pT1b1N0Mx pT1b1 (3.2 cm) uN0 (0/26, 0/5sn) Mx 13 Yes PRS III P
2. LM IB1 pT1b1N0Mx pT1b1 (2.7 cm) uN0 (0/24, 0/2sn) Mx 15 No PRS III P + PA
3. TI IB1 pT1b1N0Mx pT1b1 (3.3 cm) uN0 (0/36, 0/3sn) Mx 20 No PRS III P + PA
4. OE IB1 pT2a1N0Mx pT2a1 (3.7 cm) uN0 (0/29, 0/2sn) Mx 12 Yes PRS III P
5. KA IA2 pT1a2N0M0 pT1a2 (0.6 cm) uN0 (0/9, 0/2sn) Mx 4 No PRS II P
6. MM IB1 pT1b1N0Mx pT1b2 (5.5 cm) uN0 (0/37, 0/4 sn) Mx 12 No PRS III P + PA
7. TM IB1 pT1b1N1Mx pT1b1 (2.8 cm) uN1 (6/16, 4/7 sn, mic) Mx 10 Yes PRS III P
8. LD IB1 pT1b1N0Mx pT1b1 (0.6cm) uN0 (0/5, 0/3sn) Mx 6 No PRS III P
9. WJ IB1 pT1b1N0Mx pT1b1 (2.5 cm) uN0 (i+) (0/8, 0/1 sn, 4LN) Mx 16 Yes PRS III (LPS) P
10. JM IB1 pT2a1N0Mx pT1b1 (3.0 cm) uN0 (i+) (0/12, 0/2sn, 2 LN) Mx 9 Yes PRS III P
11. BE IB1 pT1b1N0Mx pT1b1 (0.7 cm) uN0 (0/9, 0/2sn) Mx 7 Yes PRS III P
12. KT IB1 pT1b1N0Mx pT1b1 (3.0) uN0 (i+) (0/12, 0/2sn, 1snLN) Mx 5 No PRS III (LPS) P
13. PM IB1 pT1b1N0Mx pT1b1 (1.0 cm) uN1mi, i (+) (3/5, 1/2sn, 1 LN) Mx 10 Yes PRS III P
14. WW IB1 pT1b1N0Mx pT1b1 (0.8 cm) uN0 (0/17, 0/1sn) Mx 5 No PRS III P
15. JL IB1 pT1b1N0Mx pT1b1 (2.0 cm) uN0(i+) (0/20, 0/1 sn, 4LN) Mx 15 Yes PRS III P
16. SD IB1 pT2a1N1Mx pT2a1 (3.0 cm) uN1 (19/24, 2/2sn, mic) 4 Yes PRS III P
17. PE IB1 pT1b1N1Mx pT1b1 (3.5 cm) uN1 (8/19, 4/4sn, mic) Mx 14 Yes PRS III (RSO, LS) P
18. WJ IB1 pT1b1N0Mx pT1b1 (0.8 cm) uN0 (0/15, 0/1sn) Mx 8 No PRS III (BS) P
19. OS IB1 pT1b1N1Mx pT1b1 (0.8 cm) uN1 (1/12, 0/1sn) Mx 8 Yes PRS III P
20. GB IB1 pT1b1N0Mx pT1b1 (2.4 cm) uN0 (0/53, 0/4sn) Mx 5.5 No PRS III P
21. DM IB1 pT2a1N0Mx pT2a1 (2.0 cm) uN0 (0/24, 0/3 sn) Mx 6 Yes PRS III (BS) P
22. MW IB1 pT1b1N0Mx pT1b1 (2.0 cm) N0 (0/10, 0/1sn) Mx 12.5 Yes PRS III P
23. BM IB1 pT1b1N1Mx pT1b1 (2.7 cm) uN1mi (1/20, 1/2 sn) Mx 12 Yes PRS III P
24. LM IB1 pT1b1N0 (sn) Mx pT1b1 (0.6 cm) uN0 (sn) (0/3sn) Mx 6 No PRS III (SLND) P
25. SJA IB1 pT1b1N0Mx pT1b1 (2.5 cm) uN0 (0/24, 0/3 sn) Mx 10 No PRS III P
26. KT IB1 pT1b1N0Mx pT1b1 (0.6 cm) uN0 (0/20, 0/2sn) Mx 6.1 Yes PRS III P
27. MW IB1 pT1b2N1Mx pT1b2 (4.2 cm) uN1 (6/27, 0/1 sn, mic) M1 19 No PRS III P + Pa
BS — bilateral salpingectomy; BSO — bilateral salpingo-oophorectomy, i (+) — presence of ITC; LND — lymphadenectomy; No. — case number; LPS — laparoscopy; 
P — pelvic lymphadenectomy; PA — para-aortic lymphadenectomy; PRS II,III — Piver-Rutledge-Smith surgery type II,III; R/LS — right/left salpingectomy;  
R/LSO — right/left salpingo-oophorectomy;  SLND — sentinel lymph node(s) dissection; ¶ based on routine sectioning of specimens; · based on ultrathin sectioning
25
Marcin Sniadecki et al., U-staging in early-stage cervical cancer
www. journals.viamedica.pl/ginekologia_polska
rate was 66% while using a three-step combined tech-
nique [19]. Taking the false negative results per side in 
our current study (3.7%) and the results per both sides of 
the previous study (3%), the feasibility of SLND is almost 
the same. The literature also describes cases of very low 
detection in cases of double marking [20]. Van de Lande 
et al. published their systematic review, summarizing 
23 studies (842 patients) with early-stage CC, indicating 
no difference in the cumulative sensitivity analysis of 
SLN detection of a combined technetium-colloid (99mTc) 
with the blue dye method in comparison with blue dye 
staining alone [21]. 
A high percentage of unilateral SLN detection may be 
caused by a significant number of tumors being between 
2 and 4 cm (median diameter 2.5 cm) or by the learning 
curve of performing injections. Both could affect the 
distribution of blue dye along lymphatic channels. How-
ever, due to SLN definition, it is doubtful whether, in the 
absence of bilateral SLN detection, the LNs removed from 
the non-marked side can be named as nSLN. Having nSLN 
on the non-marked side seems to be reasonable given 
the assumption that, despite the bilateral cervical flow 
of the lymph, the SLN may exist only on one side and is 
therefore independent of the method’s lymphatic mark-
ing ability. Notwithstanding, the aim of our present study 
was to evaluate the prevalence of LVLND in all the LNs 
detected with PU performance, irrespective of the quality 
of administration. 
Even though the subject of SLN in CC is not new, there 
are still only a few studies dedicated to nSLN. According to 
the authors’ knowledge, only 10 studies on PU in early-stage 
CC, including evaluation of non-SLNs, have been published 
up to the date of our study (Tab. 7) [22–31]. 
Marchiole and co-authors [30] in early 2000 evaluated 
material like ours (574 LNs in 29 patients with CC IA1[LVSI+] 
- IB1 FIGO stages), in most cases (27/29) using a single stain-
ing method. They stated that the number of false negative 
results was too high (13%) to recognize SLND as safe.
Slama et al. examined 225 patients with CC (FIGO IA2-IIB) 
in a situation in which at least one SLN was detected with 
Table 3. Cases of events in lymph nodes from the test group (n1) with additional information on tumor size, ultrastaging, SLN identification 
side, SLN and nSLN condition (according to lesion domination per site and LNs) as well as detected lesions in SLN/nSLN including stained side 
Case number 
(Initials, group 
number)
SLN detection LN condition
Positive, indeterminated or other
Right side Left side
Right side Left side
SLN nSLN SLN nSLN
1. (TM) (7) + + MAC (1) - MAC (1) - MAC (1) and MIC (1) in indeterminated LNs 
2. (WJ) (9) - + - - - ITC (4)
3. (JM) (10) + - ITC (1) ITC (1) - -
4. (KT) (12) + - ITC (1) - - -
5. (PM) (13) + + - - MIC (1) MIC (2)ITC (1)
6. (JL) (15) - + - - ITC (1) ITC (2) ITC in left parametrial LN (1)
7. (SD) (16) + + MIC (1) MAC (2)MIC (6)
MAC (1) MAC (7)
MIC (2)
8. (PE) (17) + + MAC (1) - MAC (3) MAC (3)MIC (1)
9. (OS) (19) - + - MAC (1) - -
10. (BM) (23) + + MIC (1) - - -
11. (MW) (27) + - - MIC (2) - MAC (1)MIC (2) MIC (1) in paraaortic LN 
‡ according to TNM system (2010); LN — lymph node; MAC — macrometastasis; MIC — micrometastasis; ITC — isolated tumor cells; SLN — sentinel lymph node; nSLN 
— non-sentinel lymph node
Table 4. Lymph nodes’ events deciding on staging in 11 patients 
with division into sentinel lymph nodes (SLNs) and non-sentinel 
lymph nodes (nSLNs) and isolated tumor cells (ITCs)
SLN 
status
nSLN 
status n [%] SLN-ITC nSLN-ITC
- - 4 (36.36) 3 2
- + 2 (18.18) 0 0
+ - 1 (9.09) 0 0
+ + 4 (36.36) 0 1
ALL 11 (100) 3 3
Chi-square test, p = 0.12168 - no statistically significant relationship; Left side 
of the table: positive (+) SLN or nSLN is the diagnosis of macrmetastasis(es) or 
micrometastasis(es) in the lymph node, ITC - isolated tumor cells; Right side of 
the table: the number of ITC cases in the sentinel (SLN-ITC) and non-sentinel 
(nSLN-ITC) lymph nodes, respectively
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blue dye and radiotracer and they observed a low sensitivity 
in establishing the SLN status [32]. The authors emphasized 
that a tumor size above 20cm3 and LVSI increase the risk of 
a false negative result.
In the most recent research, Cibula et al. carefully 
selected 17 cases with CC FIGO stage IB1 (≥ 3 cm, 8 pa-
tients), IB2 (7 patients), and IIB (2 patients), with bilateral 
SLN identification using an application of blue dye and 
radiotracer [31]. Their average of 2.5 SLNs per patient 
is the same as in our study. Nevertheless, Cibula et al. 
obtained 100% sensitivity in metastasis determination 
in SLN tested by PU. Due to the central position of the 
cervix, the possibility of obtaining false results in the SLN 
evaluation should be considered as associated with the 
side of the pelvis. We obtained similar results in our pre-
sent study; however, 3 false negative results per patient 
Figure 2. Distribution of lymph nodes events in 27 patients with ultrastaging performed
27
Marcin Sniadecki et al., U-staging in early-stage cervical cancer
www. journals.viamedica.pl/ginekologia_polska
were found (all in cases of unilateral detection, including 
a case with ITC), a result that can be due to our larger 
study group or to our adopted definitions. 
Zaal et al. examined a group of 645 CC patients (FIGO 
IA-IIB), and observed a prognostic benefit relating to OS 
and DFS, after removing more than 16 nSLN from tumors 
in IB2–II FIGO stages and LVLND in SLN [33]. Fregnani 
et al. reported on FIGO IB–IIA cancer stages and found 
that only a high number of pelvic LNs (> 20) affects the 
prognosis [28]. 
Sakuragi et al. performed a study on patients with 
IB1-IB2 FIGO stages and determined the frequency of 
metastases in pelvic LNs to be 11.5%, and of metastases 
in PALNs to be 2.1%, but the prognostic impact was not 
evaluated [34]. 
Nodal and distant stage migration in the PU context has 
not been evaluated to date. Meva et al. performed an analy-
sis of 54 patients with CC and presented computed tomogra-
phy (CT) findings on the individual FIGO stages. The authors 
determined there was consistency between FIGO and pTNM 
in only 59% of their cases [35]. 
It seems clear that tumors smaller than 2cm in di-
ameter have a lower risk of nSLNs and therefore limit-
ing surgery is safe. Hsu et al. indicated the crucial role 
of defining the maximal tumor diameter and proposed 
two scenarios for patients with FIGO stage IB1 cancer 
< 2cm for better control of the disease, by performing 
parametrectomy. The system incorporated resource set-
ting, frozen section of SLNs and age. In cases of positive 
SLNs on frozen section or an age < 50 in lower resource 
setting, parametrectomy can be omitted [36]. However, 
Figure 3. Graph presenting the cut-off value of the depth of tumor 
invasion for higher risk of invasion to lymph nodes
Table 5. False negative results per patient
Case description Type of change in the nSLN Labeling Commentary
40-years old, BMI 19, SCC, G2, pT = 2.5 cm, invasion 
16 mm, LVSI (+) ITC on the labeled side Left-sided only
The result is actually not false 
negative (ITC are not metastases)
62-years old, BMI 29, prior conization 3.5 weeks earlier, 
SCC, G2, pT = 0.8 cm, LVSI (-), uterine fibroids MAC on the non-labeled side Left-sided only
The result is actually not false 
negative (different sides)
57-years old, BMI 22, SCC, G3, pT = 4.2 cm, invasion 
19 mm, LVSI (-)
MIC on the labeled and non-
labeled side, one paraaortic Right-sided only The result is false-negative
BMI — body mass index; G — grade; ITC — isolated tumor cells; MAC — macrometastasis; LVSI — lymph-vascular space invasion; MIC — micrometastasis; SCC 
— squamous cell carcinoma
Table 6. Changes in the TNM staging system after histopathological ultrastaging in the test group (n1 = 27)
Feature Change Difference
Stage
· clinical (FIGO) vs. pathological 
ultrastaging, p(u)TNM 5 cases (no. 4, 10, 16, 21, 27)
· in pathology review: routine (standard processing) 
vs. ultrastaging
1. T feature
· from pT1a2 in p(u)T1b1
· from pT2a1 in p(u)T1b1
1 case (no. 6)
1 case (no. 10)
2. N feature - pN0 in p(u)N1 1 case (no. 13)
3. M feature - pMx in p(u)M1 1 case (no. 27)
Potential change in prognosis As a result of change in N feature No differences in OS and DFS (no. 13)
As a result of change in M feature No difference in OS and DFS (no. 27)
DFS — disease free survival; FIGO — International Federation of Gynecology and Obstetrics; OS — overall survival; TNM — Tumor, Node, Metastasis system
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their study was on “very early”, rather than “early” cancer 
stages [11, 15].
The under-staged patient in our study was the one who 
had the second largest tumor, pT = 4.2 cm. Two pT1b2 cases 
(pT = 4.2 cm and pT = 5.6 cm) showed the deficiencies of 
the clinical classification. Additionally, there were 6 posi-
tive LNs detected, with tumor infiltration depth of 19 mm, 
without LVSI positivity. Application of SLND procedures 
indicates that possible intra- and postoperative decisions 
should be categorically restricted to smaller tumors (ac-
cording to literature: < 4 cm, preferably ≤ 2cm or ≤ 20 cm3). 
Although imaging modalities have not been adopted in 
FIGO staging requirements and TNM, it is only rarely use 
in CC staging for early stage patients. Our study supports 
the usefulness of assessing tumor diameter, or volumetric 
modality (with ultrasound or MRI), which is also what the 
ESGO guidelines noted [13]. 
CONCLUSIONS
Micrometastases in early-stage CC (FIGO IA2-IB1) oc-
curs 2.5 times more often in SLNs than in nSLNs. Their 
detection is possible by extending the histological exami-
nation by PU. The risk of finding MICs in nSLNs increases 
with tumor size (> 2 cm) and with the infiltration of the 
lymphatic perivascular space (LVSI). Utilization of PU al-
lows information on the actual CC clinical stage to be 
obtained. The SLN status determines the state of the 
remaining LNs so long as there is a bilateral identifica-
tion of SLN. In the absence of SLN detection on one side 
one cannot reliably conclude on the status of the nodes 
on the ipsilateral side since there is the risk of obtaining 
a false diagnostic result and of underestimating the stage. 
Although selection of cases with cT ≤ 2cm and cN0 does 
not eliminate the risk of improper staging, stage mi-
gration in early CC, due to incorporation of pathologic 
ultrastaging, is less probable and yet, has an immeasur-
able prognostic and predictive impact. The only way the 
prognosis would be different will be where PU identifies 
metastases that would warrant adjuvant therapy in a set-
ting that would otherwise not receive adjuvant therapy.
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